• SyncroPatch 384

    Next level versatility and flexibility
  • SyncroPatch 384

    True HTS and GigaOhm seals
  • SyncroPatch 384

    Your multi purpose instrument
  • SyncroPatch 384

    Powerful analysis software
  • SyncroPatch 384

    Assay flexibility via high tech
  • SyncroPatch 384

    Heating and cooling of solutions, cells and patch clamp sites

2021 - Arrhythmia variant associations and reclassifications in the eMERGE-III sequencing study

icon sp96  SyncroPatch 768 PE (a predecessor model of the SyncroPatch 384 instrument) pre-print publication in MedRxiv (2021)

Glazer A. M., Davogustto G., Shaffer C. M.,Vanoye C. G., Desai R. R., Farber-Eger E. H., Dikilitas O., Shang N., Pacheco J. A., Yang T., Muhammad A., Mosley J. D., Van Driest S. L., Wells Q. S., Rinke L. L., Kalash O. R., Wada Y., Bland S., Yoneda Z. T., Mitchell D. W., Kroncke B. M., Kullo I. J., Jarvik G. P., Gordon A. S., Larson E. B., Manolio T. A., Mirshahi T., Luo J. Z.,Schaid D., Namjou B., Alsaied T., Singh R., Singhal A., Liu C., Wenig C., Hripcsak G., Ralston J. D., McNally E. M., Chung W. K., Carrell D. S., Leppig K. A., Hakonarson H., Sleiman P., Sohn S., Glessner J., the eMERGE Network, Denny J., Wie W-Q., Jr. George A. L., Shoemaker M. B., Roden D. M.


MedRxiv (2021) doi:10.1101/2021.03.30.21254549


In 21,846 eMERGE-III participants, sequencing 10 arrhythmia syndrome disease genes identified 123 individuals with pathogenic or likely pathogenic (P/LP) variants. Compared to non-carriers, P/LP carriers had a significantly higher burden of arrhythmia phenotypes in their electronic health records (EHRs). Fifty one participants had variant results returned. Eighteen of these 51 participants had inherited arrhythmia syndrome diagnoses (primarily long QT syndrome), and 11/18 of these diagnoses were made only after variant results were returned. After in vitro functional evaluation of 50 variants of uncertain significance (VUS), we reclassified 11 variants: 3 to likely benign and 8 to P/LP. As large numbers of people are sequenced, the disease risk from rare variants in arrhythmia genes can be assessed by integrating genomic screening, EHR phenotypes, and in vitro functional studies.

Download here

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.